VAI–Stand Up To Cancer Epigenetics Dream Team

The Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team fosters collaboration between several of the world’s most respected research and clinical organizations in an effort to translate scientific discoveries into new standards of patient care.

It was established in 2014 and builds on the foundations laid by the first iteration of the SU2C Epigenetics Dream Team, which was founded in 2009. Today’s team is based at Van Andel Institute in Grand Rapids, Michigan, and is led by the Institute’s Chief Scientific Officer Peter Jones, Ph.D., D.Sc., and Stephen Baylin, M.D., VARI Director’s Scholar and co-head of Cancer Biology at Johns Hopkins University’s Sidney Kimmel Comprehensive Cancer Center.

VAI’s Pathology and Biorepository Core supports the VAI–SU2C Epigenetics Dream Team clinical trials through biospecimen collection kit production, distribution and tracking, biospecimen receipt, handling and storage, biospecimen processing to analytes (such as DNA and RNA), and the distribution of analytes for genomic characterization.